Brokerages Set Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) PT at $4.93

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has received a consensus rating of “Hold” from the eight analysts that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, four have issued a hold recommendation, two have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $4.9250.

Several brokerages recently issued reports on IRWD. Citigroup upgraded Ironwood Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Monday, January 5th. Wells Fargo & Company raised their price target on shares of Ironwood Pharmaceuticals from $3.00 to $5.00 and gave the stock an “equal weight” rating in a research report on Monday, January 5th. Citizens Jmp lifted their price target on shares of Ironwood Pharmaceuticals from $8.00 to $10.00 and gave the company a “market outperform” rating in a report on Thursday, February 26th. Weiss Ratings reiterated a “sell (d)” rating on shares of Ironwood Pharmaceuticals in a research note on Monday, December 29th. Finally, Zacks Research cut shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th.

Ironwood Pharmaceuticals Stock Performance

Shares of IRWD stock opened at $3.74 on Monday. The stock has a market capitalization of $608.42 million, a price-to-earnings ratio of 28.77 and a beta of 0.24. Ironwood Pharmaceuticals has a one year low of $0.53 and a one year high of $5.78. The company’s 50-day simple moving average is $4.31 and its 200-day simple moving average is $2.89.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.03). Ironwood Pharmaceuticals had a net margin of 8.11% and a negative return on equity of 13.72%. The firm had revenue of $47.71 million for the quarter, compared to analyst estimates of $86.10 million. As a group, research analysts forecast that Ironwood Pharmaceuticals will post 0.1 EPS for the current year.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Several large investors have recently added to or reduced their stakes in IRWD. Integrated Wealth Concepts LLC boosted its holdings in shares of Ironwood Pharmaceuticals by 21.4% during the third quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 3,406 shares during the period. Focus Partners Advisor Solutions LLC lifted its position in Ironwood Pharmaceuticals by 284.6% in the 2nd quarter. Focus Partners Advisor Solutions LLC now owns 39,743 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 29,409 shares during the last quarter. LSV Asset Management acquired a new position in Ironwood Pharmaceuticals during the 4th quarter valued at about $30,000. Captrust Financial Advisors bought a new position in Ironwood Pharmaceuticals in the 2nd quarter worth about $32,000. Finally, Jump Financial LLC bought a new position in Ironwood Pharmaceuticals in the 4th quarter worth about $34,000.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.